ILD type | Serology obtained (N = 605) | Positive serologyb | Positive clinical signs or symptoms suggestive of autoimmune diseasec | Duration of disease cohort follow-up, months (median (IQR)) | Subsequent development of CTD after initial visit, N (%) |
---|---|---|---|---|---|
IPF (N, (%)) | 197 (32.6) | 51 (25.8) | 19 (6.9) | 9.2 (1.05–35.1) | 0 |
Unclassifiable ILD (N, (%)) | 146 (24.1) | 46 (31.5) | 24 (10.8) | 12.6 (0.3–47.5) | 3 |
Other IIP (N, (%)) | 92 (15.2) | 24 (26.1) | 21 (15.9) | 9.7 (0.6–52.8) | 1 |
Hypersensitivity pneumonitis (N, (%)) | 70 (11.6) | 22 (31.4) | 10 (9) | 9 (0.6–44.7) | 0 |
CTD-ILD ((N, (%)) | 42 (6.9) | 41(98) | 38 (90) | 14.8 (0.9–66.6) | - |
Drug induced/Environmental (N, (%)) | 15 (2.5) | 4 (26.7) | 0 | 6.2 (1.7–50) | 0 |
Rare ILDa (N, (%)) | 11 (1.8) | 3 (27) | 2 (7.1) | 16.2 (0.1–59.7) | 0 |
IPAF (N, (%)) | 18 (2.9) | 14 (78) | 13 (72) | 17.3 (1.8–55.1) | 0 |
Sarcoidosis (N, (%)) | 5 (0.82) | 2 (40) | 1 (9) | 4.1 (0.6–33.8) | 0 |
CPFE (N, (%)) | 4 (0.66) | 2 (50) | 0 | 28.4 (3.3–55.1) | 0 |
Aspiration-related fibrosis (N, (%)) | 1 (0.16) | 0 (0) | 1 (16.6) | 55.7 (−) | 0 |
ANCA vasculitis related ILD (N, (%)) | 4 (0.66) | 4 (100) | 4 (80) | 80.9 (25–96.7) | 0 |